CWRUObserver.com -Financial News and Headlines - NYSE, Nasdaq, OTC's

[Rager]

EGEI - eGene's HDA-GT12 Genetic Analyzer Demonstrates the Rapid H5N1 Avian Influenza Virus Detection; The System Could Be Developed as an Effective Pathogen Detection Platform
May 4, 2007 12:55:00 PM
Copyright Business Wire 2007
IRVINE, Calif.--(BUSINESS WIRE)--

eGene Inc. (OTCBB:EGEI), developer of a revolutionary high-performance genetic analysis technology, announced today that its HDA-GT12(TM) demonstrates rapid detection of the H5N1 avian influenza virus. The technical article appears in American Biotechnology Laboratory April, 2007 (Vol. 25, No. 5) issue, in the story: "Rapid H5N1 Subtype Avian Influenza Virus Detection." http://www.americanbiotechnologylaboratory.com/articles/index.php?3- all-abl/b0407lee.pdf

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

eGene and the Genome Institute of Singapore (GIS) have worked together to develop a rapid, highly sensitive, and cost-effective screening approach for H5N1 avian influenza virus detection. The HDA system, in combination with the GIS's single-step RT-PCR, is a simple and sensitive assay for H5N1 avian influenza detection that can detect as few as 10 copies of the viral RNA.

"Our system platform provides an efficient way for pathogen detection in molecular diagnostic markets. After the recent merger announcement with Qiagen, we believe the combined companies can accelerate the availability of our technologies into the market and into the hands of more customers and to benefit mankind," said Ming S. Liu, Ph.D., Chief Executive Officer of eGene.

About eGene Inc.

eGene developed the HDA-GT12(TM) (high performance DNA analyzer for genotyping on 12 channels). The system analyzes the genetic fingerprints of living organisms. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of RNA in gene expression market. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.

eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzers systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize biomolecules including DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.

This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to publicly release any revision, which may be made to reflect events or circumstances after the date hereof.

Source: eGene Inc.



----------------------------------------------
Martin E. Janis & Company
Inc.
Beverly Jedynak
312-943-1100
ext. 12
[e-mail]